T
he solitary pulmonary nodule (SPN) is defi ned as a radiographic opacity Յ 3 cm in diameter with at least two-thirds of its margins surrounded by lung parenchyma. 1, 2 Implied in this defi nition is the exclusion of lymph nodes, atelectasis, and postobstructive pneumonia. However, it may be diffi cult at times to exclude intraparenchymal lymph nodes based on just radiologic appearance. SPNs have been noted in 0.09% to 7% of all chest radiographs. [3] [4] [5] A review of eight large studies on lung cancer screening using CT imaging [6] [7] [8] [9] [10] [11] [12] [13] documented the prevalence of SPN from 8% to 51%, and the prevalence of malignancy from 1.1% to 12%. 14 The etiologic spectrum of SPN represents a veritable minefi eld of diseases, including benign conditions such as hamartomas to potentially fatal ones such as primary lung cancer ( Table 1 ) . Establishing the etiology of a SPN in a timely and accurate manner, therefore, assumes critical importance, since surgical resection in a patient with early-stage lung cancer provides the highest chance of cure. By the same token, avoiding thoracic surgery for a benign SPN whenever possible does obviate signifi cant morbidity. We will describe an algorithmic approach to diagnosis of SPN in Part 2 (see page 840). 15 
Clinical Evaluation
A SPN does not typically herald its presence with clinical symptoms, nor does it lend itself to self-awareness like melanoma or a breast lump. Although the SPN may be insidious, a variety of clinical risk factors such as advancing age and history of smoking have been associated with a higher OR of the SPN being malignant. [15] [16] [17] [18] [19] Elucidating a thorough history of prior malignancy is crucial; the majority of SPNs detected in patients with a history of prior malignancy are malignant. [20] [21] [22] Interestingly, the malignant SPNs are equally or more likely to represent primary lung cancer rather
The solitary pulmonary nodule (SPN) is frequently encountered on chest imaging and poses an important diagnostic challenge to clinicians. The differential diagnosis is broad, ranging from benign granulomata and infectious processes to malignancy. Important concepts in the evaluation of SPNs include the defi nition, morphologic characteristics via appropriate imaging modalities, and the calculation of pretest probability of malignancy. Morphologic differentiation of SPN into solid or subsolid types is important in the choice of follow-up and further management. In this fi rst part of a two-part series, we describe the morphologic characteristics and various imaging modalities available to further characterize SPN. In Part 2, we will describe the determination of pretest probability of malignancy and an algorithmic approach to the diagnosis of SPN. than metastasis from the extrapulmonary malignancy, with the notable exceptions of sarcoma, melanoma, and testicular carcinoma ( Table 2 ). The presence of mediastinal lymph node enlargement on CT scan strongly suggests a new primary lung cancer rather than metastasis. 20 Interstitial lung diseases, such as idiopathic pulmonary fi brosis, asbestosis, and scleroderma are associated with an increased incidence of lung cancer. 23 The prevalence of lung cancer in idiopathic pulmonary fi brosis, for example, ranges from 9% to 38%, with a predilection for peripheral lung areas in the lower lobes in elderly male smokers. [24] [25] [26] [27] [28] [29] Finally, residence in or travel to an area with endemic fungal pathogens could suggest a benign, infectious SPN in the correct clinical context. For example, coccidioidomycosis is endemic in the southwestern United States and Mexico, and often presents as a SPN on chest CT scans. 30 Cryptococcus 31-33 infection and histoplasmosis can also present as a SPN.
Radiographic Characteristics: CT Scan
Specifi c morphologic characteristics of SPNs on imaging may help differentiate benign from malignant SPNs. It is recommended that CT images be thin section, with contiguous 1-mm images through nodules. Both lung and mediastinal windows should be obtained, the former for the edges, the latter for solid components. Low-dose (milliamperes second [mAs] , 80) CT scan can be used for this purpose.
Growth Rate
Malignant, solid SPNs have a volume doubling time of 20-400 days, [34] [35] [36] [37] [38] with a majority having volume doubling times of signifi cantly , 100 days. 39 A volume doubling time . 400 days suggests slow growth and is usually associated with benign SPNs, whereas volume doubling time , 20 days indicates very rapid growth, usually attributable to infectious processes. 40 It is important to realize that since the volume of a sphere equals 4 p r 3 /3, an increase in nodule diameter by only 26% indicates doubling of volume. In other words, a as pure ground glass nodules (GGNs), as will be discussed separately.
Size
The likelihood of malignancy in a SPN increases with the nodule diameter 47, 48 ( Fig 2 ) . Lesions larger than 3 cm are more likely to be malignant. However, a smaller size does not exclude malignancy.
Location
SPNs in the upper lobes have been observed to be malignant in a larger number of cases. 17, 49, 50 This is possibly because there is a higher concentration of inhaled carcinogens in the upper lobes resulting from cigarette smoking. 40 
Margin/Border/Edge Characteristics
Furuya et al 51 divided margins of SPNs into seven categories: smooth, lobulated, spiculated, ragged, tentacle, polygonal, and with surrounding halo and with notches or concavity. The described margin types and their possible etiologies are shown in Table 3 and Figures 3-8 . 16, 47, [51] [52] [53] [54] [55] [56] [57] [58] [59] 
Calcifi cation and Attenuation
Specifi c patterns of calcifi cation within a SPN (diffuse, central [bull's eye], laminated or concentric, or popcorn) can suggest a benign lesion ( Figs 9-12 ). However, there is no pattern of calcifi cation that is considered specifi c for malignancy 60 ( Table 4 40, [61] [62] [63] [64] [65] ). The plain chest roentgenogram is not very sensitive in detecting calcification within a SPN, demonstrating a sensitivity of 50% and a specifi city of 87%. 66, 67 Hence, a noncontrast CT scan with 1 to 3 mm sections through the nodule is recommended to assess the SPN and the calcifi cation within the SPN. Attenuation values . 200 Hounsfi eld units in a SPN indicate the presence of calcium in the nodule. 68 4-mm nodule may double in volume, but its size will barely increase to 5 mm, a change often too subtle to detect reliably on CT scans. 41 Three-dimensional volumetric measurement of a SPN on a CT scan of the chest can provide a more accurate assessment of growth rate compared with the SPN diameter, especially in small ( , 1 cm) SPNs ( Fig 1 ) . [42] [43] [44] However, it must be pointed out that there is signifi cant controversy regarding the most accurate method to follow the rate of growth of nodules. There are those who advocate for volumetric analysis, but this is generally applicable for solid lesions . 8 to 10 mm. The data for smaller lesions are less compelling. It should also be stated that for ground glass and subsolid nodules, assessment of growth rate is even less clear. These lesions may be followed by assessing their mass, that is, a combination of both volume and density. 45, 46 To date, there is no consensus on the best way to follow these lesions. In general, a solid SPN, stable in volume over a period of 2 years (which indicates a doubling time . 730 days) can be reliably considered benign; important exceptions to this rule are slow-growing adenocarcinomas of the lung, especially those presenting pneumonia and pulmonary metastases from liposarcoma (almost always solid-appearing lesions), and renal cell carcinoma. 70, 71 Cavitation Cavitation can be seen in necrotic malignant SPNs like squamous cell carcinoma, as well as benign SPNs such as abscesses, infectious granulomas, vasculitides, early Langerhans cell histiocytosis, and pulmonary infarction. Cavity wall thickness , 5 mm points toward a benign etiology, whereas irregular and thicker walls . 15 mm are seen with malignant lesions, although this is not always true ( Fig 14 ) . 72, 73 Small lucencies in a SPN may be seen in adenocarcinomas in situ or lepidic predominant adenocarcinomas (both previously known as bronchoalveolar carcinoma) ( Figs 15, 16 ) . 74, 75 This pattern, often referred to as "bubbly lucencies," can also be seen in pulmonary lymphoma, sarcoidosis, round pneumonia, and organizing pneumonia. 70, 76, 77 Sometimes, fl uid-fi lled lesions from mucus impaction can appear as cavitating SPN.
Ground Glass Nodules
Pulmonary nodules can be characterized on CT scan as either solid or subsolid. Solid nodules completely
Fat
An attenuation value of a SPN between 2 40 and 2 120 Hounsfi eld units suggests the presence of fat, which is present in up to 60% of hamartomas 52, 69 ( Fig 13 ) . Rare causes of fat attenuation include lipoid 55, 56 Adenocarcinoma in situ (previously known as bronchoalveolar carcinoma) can also produce a halo, due to its lepidic growth. Notches SPN with notches or concavity in the margin is seen in some SPNs with tumor growth. These notches are frequently found in adenocarcinomas with overt invasion and are associated with poor prognosis. 57 PPV 5 positive predictive value. See Table 2 legend for expansion of other abbreviation. (FDG)-PET scan fails to demonstrate activity. In a study of lung cancers identifi ed at screening CT imaging, the volume doubling time was higher for this spectrum of adenocarcinomas (988 Ϯ 470 days for atypical adenomatous hyperplasia and 567 Ϯ 168 days for bronchoalveolar carcinoma) compared with squamous cell carcinomas (122 Ϯ 68 days). 80 Tsunezuka et al 81 found that on FDG-PET imaging, the false-negative rate for nodules that would include adenocarcinoma in situ, minimally invasive adenocarcinomas, and lepidic predominant adenocarcinomas in the new IASLC/ ATS/ERS adenocarcinomas classifi cation (formerly known as Noguchi lesions of type A, type B, and type C 82 ) were 100%, 80%, and 47%, respectively, while the true-positive rate for overtly invasive adenocarcinomas (formerly Noguchi types D, E, and F lesions) was 81.8%. Similar results were reported by Yap et al. 83 Thus, it appears that subsolid nodules may often be malignant and yet demonstrate a doubling time . 2 years or a negative PET scan. Management of GGNs is controversial at this time. Based on current literature and taking into consideration the aforementioned issues, we have proposed an alternative approach for subsolid nodules, as seen in our diagnostic algorithm. This approach does not differentiate between low-and high-risk groups, as per the original Fleischner criteria, 48 because adenocar cinomas frequently affect younger and nonsmoking patients. obscure the lung parenchyma. In distinction, subsolid nodules include both pure GGNs ( Fig 17 ) and partly solid GGNs ( Fig 18 ) . GGNs are defi ned as focal nodular areas of increased lung attenuation through which normal parenchymal structures such as airways, vessels, and interlobular septa are visible. 78 GGNs are frequently multiple and the approach to multiple GGNs is different from solitary GGNs; however, it is out of scope of this article.
As recently characterized by the International Association for the Study of Lung Cancer (IASLC), the American Thoracic Society (ATS), and the European Respiratory Society (ERS), subsolid nodules frequently represent the histologic spectrum of adenocarcinomas, including atypical adenomatous hyperplasia, adenocarcinomas in situ, minimally invasive adenocarcinomas, and lepidic predominant adenocarcinomas ( Figs 16A-C, 17 ) . 79 The CT scan patterns recognized in the new IASLC/ATS/ERS lung adenocarcinoma classifi cation are summarized in Table 5 . 79 The presence of more solid components in the GGN on the CT scan is associated with more invasive pathologic features. Despite this correlation, distinguishing benign from malignant subsolid nodules based on radiologic characteristics alone remains problematic, owing to their slower growth rate and correspondingly low metabolic activity. Clinically, this translates to the likelihood of malignancy still being signifi cant even if no growth is demonstrated in a SPN over 2 years or if the 18 F-2-deoxy-2-fl uoro-d -glucose assessment of their growth rate when their diameter is . 8 mm. It might be suitable to assess changes in tumors by tumor activity, which can be measured by FDG uptake on PET scan, but experience with combined PET-CT imaging in this setting is still limited at this time. Only a few series have assessed the role of combined PET-CT imaging in response to radiotherapy, and there are no data supporting an approach involving serial PET scans to assess nodule size. 84 Size PET scans are recommended only for nodules that are . 8 to 10 mm in diameter because the sensitivity decreases for the smaller pulmonary nodules. Nodules , 1 cm and GGN have a high rate of falsenegative interpretation.
SUV Characteristics
The metabolic activity of a nodule is quantifi ed using the SUV; a high SUV indicates increased FDG uptake due to high metabolic activity, which is suggestive of malignancy. A mean SUV value . 2.5 is the cutoff at which PET scan has optimal sensitivity and specifi city. 85 Combined PET-CT scan studies can be evaluated in a number of different ways. One method is to measure the SUV level. Another method is to grade the confi dence of malignancy by visual analysis. This is done by the nuclear radiologist using a grading system that compares the SUV to the normal FDG uptake Radiographic Characteristics:
Combined PET-CT Imaging
Combined PET-CT imaging is a relatively new multimodality technology that allows the correlation of results from two simultaneous and complementary imaging modalities. The CT imaging component demonstrates anatomic detail but does not provide functional information, whereas FDG-PET imaging reveals aspects of tumor function and metabolism. With combined PET-CT imaging, as with CT imaging alone, there are specifi c characteristics of SPNs on imaging that may help differentiate benign from malignant disease. Malignant cells are more metabolically active and import glucose more avidly than other tissues. This concept forms the basis for PET imaging, which is performed after administration of a glucose analog that has been tagged with a positron-emitting isotope of fl uorine, FDG. Whereas the CT image delineates the anatomy of the SPN, the FDG-PET scan, in essence, reveals its pathophysiology. A nodule's metabolic activity is quantifi ed using the standardized uptake value (SUV); a high SUV indicates robust FDG uptake due to high metabolic activity, which suggests malignancy ( Fig 19 ) .
Growth Rate
Currently, three-dimensional volumetric measurement of SPNs on CT chest scan provides an accurate 
Diagnostic Accuracy of Imaging Modalities

Chest Radiographs
The chest radiograph is not recommended as a screening tool for lung cancer, and indeed has a very low sensitivity for detecting SPNs. 39 A signifi cant number of SPNs are missed on chest radiographs, even by experienced radiologists, especially in the upper lobes and peripheral lung zones where they may be obscured by bony structures. [89] [90] [91] [92] [93] Moreover, the chest radiograph lacks suffi cient resolution to visualize the morphologic characteristics of SPNs discussed previously. If a SPN is visible on chest radiograph, and if a previous radiograph is not available to demonstrate stability over Ն 2 years, a CT scan of the chest should be performed with thin sections through the nodule to better delineate its morphology.
CT Scan
The CT scan is more sensitive than the chest radiograph in detecting SPNs, as it eliminates superimposition within the thorax. Both methods are accepted, but in most cases measuring the SUV does not improve diagnostic accuracy beyond that obtained with simple visual interpretation. 86 In diffi cult cases, prolonged observation of the metabolic activity of the nodules has proven to help in the differential diagnosis. There are data that suggest that dual time-point FDG-PET scanning may improve sensitivity and possibly specifi city in the evaluation of pulmonary nodules, especially in small-to medium-sized nodules if the nodules retain a higher percentage of their activity at Ն 2 h. 87 However, this is not currently recommended given the paucity of data and the confl icting fi ndings in different studies.
It should be noted that variations in body habitus, duration of the uptake period, plasma glucose levels, and partial-volume effects can create marked fl uctuations in SUV levels. In these situations, combined PET-CT imaging can be falsely positive or negative and this needs to be taken in consideration in complex cases. 88 to have positive lymph node involvement during surgical sampling. [94] [95] [96] [97] [98] This suggests that an important clue to the benign vs malignant nature of a SPN, that is, involvement of hilar and mediastinal lymph nodes, is missed quite often on CT scan. Indeed, meta-analyses on the accuracy of CT scanning for staging the mediastinum in patients with lung cancer have revealed a sensitivity of only 51% to 64% and a specifi city of 74% to 86%. [99] [100] [101] Studies specifi cally looking at stage T1 lung cancer have found even lower sensitivity: 27% to 41%. 96, 102 CT imaging of the chest also does not take into account the possibility of distant metastases from a malignant SPN, which, albeit infrequent, should nevertheless not be ignored. 103 Some centers have studied the utility of lack of contrast enhancement of a nodule to point toward a benign etiology. However, as will be mentioned in the next section of this article, combined PET-CT scans, by shedding of structures. The SPN, once visualized on CT scan, can provide clues as to its nature, that is, benign vs malignant, based on the morphologic characteristics discussed previously in this article. 39 Initially, there was enthusiasm about CT imaging with dynamic contrast enhancement, but with the advent of PET scan it has been marginalized.
In patients with a CT scan-based evaluation of a likely malignant, solid SPN (clinical T1N0M0 or stage I lung cancer), 5% to 21% patients are still found See Table 2 legend for expansion of abbreviation.
(82.3% vs 40.6%). In this study, PET scan was also found to have superior interobserver and intraobserver reliability, compared with CT imaging. The average nodule size in this study was 16 mm. 107 In a retrospective study of 100 patients, 40 of whom had malignant SPNs, the sensitivity values for CT, PET, and integrated PET-CT scans were 82%, 88%, and 88%, respectively, whereas the specifi city values were 66%, 71%, and 77%, respectively. 108 PET-CT imag ing provided signifi cantly better specifi city than CT scan alone or PET scan alone, and had a positive predictive value (PPV) of 72% and a negative predictive value (NPV) of 90%. The higher specifi city of PET-CT imaging was attributed to the ability to discard false-positive PET scan uptake on the basis of CT scan morphology showing benign patterns of calcification. Another retrospective analysis of 119 patients, 79 of whom had malignant SPNs, yielded sensitivity, specifi city, and accuracy of 96%, 88%, and 93%, respectively, with integrated PET-CT imaging; this accuracy was higher than contrast-enhanced CT scan. The NPV of PET-CT scanning was 92%, leading the authors to conclude that a SPN with a negative PET-CT scan could safely be followed up over time. 109 Several other studies have yielded similarly high sensitivity and accuracy for integrated PET-CT scan ning. [110] [111] [112] Interestingly, these studies found that visual analysis of SUV yields better accuracy than semiquantitative analysis; in other words, considering any uptake on PET scanning as malignant yields better sensitivity than considering a particular SUV cutoff. light on both anatomic and functional characteristics of the nodule, have replaced CT scan with contrast enhancement for this purpose. It should be pointed out that in November 2010, the National Lung Cancer Screening Trial reported 20% fewer lung cancer deaths among trial participants screened with lowdose helical CT scan compared with those who were screened with chest radiographs. It is, therefore, very likely that more SPNs will be detected in the future, thus escalating the importance of clinical and radiographic guidelines for its management. 104 
FDG-PET/Combined PET-CT Scanning
FDG-PET scanning is very accurate in differentiating benign from malignant lesions in nodules as small as 1 cm. A meta-analysis of 12 studies with 624 patients demonstrated a sensitivity of 96%, specifi city of 79%, and accuracy of 91%. 105 Gould et al 106 reported a sensitivity of 94.2% and specifi city of 83.3% in a metaanalysis of 13 studies evaluating 450 patients with nodules . 8-10 mm. Another review of 17 studies revealed a sensitivity of 80% to 100% and specifi city of 40% to 100%; pooled sensitivity and specifi city values were 87% and 83%, respectively, for nodules measuring . 8-10 mm. 90 In a subsequent prospective study of 344 participants, the sensitivities of PET and CT imaging to aid detection of a malignant nodule were found to be similar (91.7% vs 95.6%), but the specifi city of PET scans was superior to CT scans It is important to understand the shortcomings of PET scanning. The sensitivity of detecting SPNs , 8 to 10 mm in diameter is low, likely because the mass of metabolically active cells is too small to be detected with the aid of PET scanning, so its use in such nodules should be avoided. 115 Tumors that have low metabolic activity (eg, adenocarcinomas in situ, carcinoids) can In addition to its accuracy in determining the benign vs malignant nature of a SPN, combined FDG-PET scanning provides additional clues in the form of an evaluation of the mediastinal lymph nodes for possible metastases. In a meta-analysis of 44 studies with 2,865 patients with lung cancer, the sensitivity and specifi city for identifying mediastinal metastases with PET scans were 74% and 85%, respectively, which is more accurate than CT scanning. 99 In a retrospective study of 184 patients with clinical stage T1 non-small cell lung cancer (NSCLC), pathologic N2 disease was identifi ed in 23 (12%) patients. PET-CT scanning had an N2-disease detection sensitivity of 48%, specifi city of 95%, and accuracy of 89%. 113 In another prospective study of 150 patients with clinical stage T1 NSCLC, the sensitivity, specifi city, PPV, NPV, and accuracy of combined PET-CT scanning in detecting mediastinal nodal involvement were 47%, 100%, 100%, 87%, and 88%, respectively. 114 The low sensitivity of combined PET-CT scans in stage T1 NSCLC is likely attributed to its inability to detect early-stage or microscopic metastases. Although more studies are needed to assess the role of combined PET-CT scanning in stage T1 NSCLC, that is, malignant SPNs, it appears that the high specifi city and accuracy can be used to an advantage while evaluating SPNs. The lack of mediastinal uptake should not rule out the possibility of malignancy, but the presence of uptake should serve as a clue that malignancy is a possibility. patients with malignant SPNs and false-negative FDG-PET scan results may have a favorable prognosis even when curative intent surgery is delayed by up to 238 days. 119, 120 Therefore, patients with negative fi ndings on FDG-PET scan should still be followed up with serial imaging for at least 2 years to confi rm a benign diagnosis. False-positive results are also well described, not only for the SPN but for the mediastinum: Infectious and infl ammatory conditions such as TB, endemic mycoses, sarcoidosis, and others can yield false-positive results. Tissue biopsy specimens therefore remain the gold standard in elucidating the fi nal diagnosis of the SPN. The advantages and disadvantages of PET scanning are tabulated in Table 6 .
Paradoxically, in subsolid nodules, FDG-PET scan can reveal higher SUV in infl ammatory nodules compared with malignant nodules, as shown in a study by Chun et al. 121 Similarly, Tsushima et al 122 found that SUV . 1.5 is suggestive of a benign etiology in SPN with subsolid components on FDG-PET scan. Given this paradox, FDG-PET imaging cannot be reliably used to differentiate benign vs malignant subsolid SPN. In addition, there is a low incidence of nodal and distant metastasis in subsolid nodules, which lowers FDG-PET scan sensitivity. 123 
MRI
New literature is emerging regarding the use of dynamic MRI to distinguish benign from malignant SPN. Dynamic MRI values have been found to refl ect the quantitative and morphologic characteristics of microvessels in SPNs, similar in concept to dynamic CT imaging. 124 In a study of 202 SPNs, 125 dynamic MR images were obtained before and up to 8 min after IV injection of gadopentetate dimeglumine using yield false-negative results, as discussed previously. Finally, a signifi cant number of false-negative results have been found in high-risk patient populations, notably SPNs detected during screening studies. [116] [117] [118] Although nodules , 1 cm and GGN accounted for a fair share of the false-negatives, it nevertheless appears that FDG-PET imaging is most suited to evaluating SPNs with intermediate pretest probability of malignancy. Patients with a high pretest probability should proceed to a surgical biopsy procedure even if an FDG-PET scan is negative. Interestingly, T1-weighted spin-echo sequences. With Յ 110% maximum enhancement ratio as a cutoff value, the PPV for malignancy was 92%; sensitivity, 63%; and specifi city, 74%. With Ն 13.5%/min slope as a cutoff value, sensitivity, specifi city, PPV, and NPV for malignancy were 94%, 96%, 99%, and 74%, respectively. A prospective study of 175 patients with 202 SPNs 126 was recently performed comparing dynamic MRI, dynamic CT imaging, and PET-CT imaging to distinguish benign from malignant SPNs. On dynamic MRI, with a slope of enhancement ratio cutoff of 0.04/s, the sensitivity, specifi city, PPV, NPV, and accuracy were 96.3%, 82.1%, 95.7%, 84.2%, and 93.6%, respectively. These results were superior to combined PET-CT and dynamic CT imaging, and have opened up a promising new avenue of research in the use of imaging modalities to characterize SPNs.
Conclusion
Morphologic characteristics of SPN can help distinguish benign from malignant SPNs. These features include volume doubling time, size, margins, presence and nature of calcifi cation, presence of fat, and wall thickness in case of cavitation. GGNs, while usually multiple, are further classifi ed as pure ground glass and partly solid. Thin-section CT scans allow accurate delineation of these morphologic features. In conjunction, FDG-PET scans provide a window to the metabolic activity of the nodules, giving valuable pathophysiologic information about them. 
